GNRHR and posterior cortical atrophy: In the PRONOUNCE randomized trial conducted to compare the cardiovascular safety of degarelix, a GnRH receptor antagonist, with leuprolide, a GnRH receptor agonist, in patients with advanced PCa, a major adverse cardiovascular event was noted in 15 (5.5%) patients belonging to the degarelix group and 11 (4.1%) patients in the leuprolide group (hazard ratio, 1.28 [95% CI, 0.59–2.79]; p = 0.53) [37,38,39].